Skip Ribbon Commands
Skip to main content
Translate
Translate
menu iconMenu
search iconSearch

UC San Diego Moores Cancer Center Offers New Hope for Deadly Brain Tumor

 

February 03, 2012  |  

One of few clinical trial sites, worldwide

Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM).  In the United States, each year, approximately 10,000 patients are affected by GBM.  Now, a novel investigational device – available only at clinical trial sites – is offering new hope to these patients.

The non-invasive procedure – called Tumor Treating Fields (TTF) – is delivered using a portable device – called the NovoTTF-100A System made by Novocure.  The TTF procedure uses alternating electrical fields to disrupt the rapid cell division exhibited by cancer cells. 
 

 Santosh Kesari
Santosh Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego Moores Cancer Center.
“Patients with recurrent GBM present a significant treatment challenge,” said Santosh Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego Moores Cancer Center.  “The initial clinical research for the approval trial demonstrated that, compared to patients who were treated with chemotherapy, patients treated with NovoTTF achieved comparable survival times, had fewer side effects, and reported improved quality of life.”

 

On average, a patient with GBM survives less than 15 months with optimal treatment and only three to five months without additional effective treatment.  The TTF procedure may provide physicians with a fourth treatment option in addition to surgery, radiation therapy and chemotherapy.

TTFs inhibit tumor growth by causing cancerous cells to die.  The TTF procedure is delivered using non-invasive, insulated transducer arrays (electrodes) that are placed directly on the skin in the region of the tumor.  The hat-like collection of electrodes connects to a portable device which is slightly thicker than a laptop and weighs about six pounds.  The device sends a low intensity, alternating electric field into the tumor which prevents the cells from dividing and spreading and causes cancer cells to die. 

The most commonly reported side effect from NovoTTF is a mild-to-moderate scalp rash, beneath the electrodes.  The FDA-approved device is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

“When all other options have been exhausted, patients are willing to do just about anything to keep the tumor at bay,” said Kesari.  “This device gives them an opportunity to fight back, to feel like they are taking an active, hands-on role in their own treatment, and provides tremendous hope.”

# # #

Media Contact: Kim Edwards, 619-543-6163, kedwards@ucsd.edu


Related Specialties



Media Contact

Related News

4/22/2015
UC San Diego Health System and Scripps Health are partnering to provide improved continuity of patient care, fellowship training and research in hospice and palliative medicine. Under a new five-year ...
4/20/2015
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have discovered a molecular mechanism that connects breast tissue stiffness to tumor metastasis and p ...
4/20/2015
A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Die ...
4/20/2015
The threat of falsified medications, also referred to as counterfeit, fraudulent, and substandard, can be quite real, yet the full scope and prevalence of the problem is poorly understood, say researc ...
4/17/2015
Researchers at the University of California, San Diego School of Medicine have created an in vitro, live-cell artificial vessel that can be used to study both the application and effects of devices us ...
4/16/2015
The increase in use of e-cigarettes has led to heated debates between opponents who question the safety of these devices and proponents who claim the battery-operated products are a useful cessation t ...
4/16/2015
An international team of scientists, led by researchers at University of California, San Diego School of Medicine, have found genetic overlap between Alzheimer’s disease (AD) and two significant cardi ...
4/13/2015
About one quarter of all atrial fibrillation patients at the lowest risk for stroke receive unnecessary blood thinners from cardiology specialists, according to a new study by researchers at Universit ...


Share This Article



Follow Us